
Advamed report finds racial disparities in care, proposes fixes
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: White Medicare patients are 50%
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: White Medicare patients are 50%
TORONTO, March 11, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“Psyence Group” or the “Company“) (CSE:PSYG) of the closing (the
In a landmark study on the “moral status” of psilocybin, nearly 9 out of 10 Americans have voiced their approval for the controlled, licensed use
At the forefront of medical innovation, the Cleveland Clinic is pioneering a study that revisits the potential of psychedelics, substances traditionally linked with recreational use,
Share this article Sanofi’s investigational drug amlitelimab is forecast to generate $581m in sales by 2030, as per GlobalData analysis. Credit: Golden Shrimp via Shutterstock.
Share this article Oligonucleotide therapeutics offer highly specific and effective treatments for both rare diseases and more common conditions. Research on antisense oligonucleotides (ASOs) began
Share this article Cresemba is approved as an injection and capsule for the treatment of pediatric invasive aspergillosis and invasive mucormycosis. Image credit: JHVEPhoto/Shutterstock.com Following
Share this article Novo Nordisk’s obesity drugs, Wegovy and Saxenda, generated DKr41.5bn ($6.1bn) in global sales in 2023, as per Novo’s 2023 annual report. Image
Share this article The indicated that the accelerated approval pathway could be an option for marketing due to positive clinical evidence. Image credit: Shutterstock/nobeastsofierce. Mesoblast’s
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online